Ad35 and Ad26 Vaccine Vectors Induce Potent and Cross-Reactive Antibody and T-Cell Responses to Multiple Filovirus Species

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Zahn, Roland ^a   Gillisen, Gert ^a   Roos, Anna ^a   Koning, Marina ^a   van der Helm, Esmeralda ^a   Spek, Dirk ^a   Weijtens, Mo ^a   Grazia Pau, Maria ^a   Radošević, Katarina ^a   Weverling, Gerrit Jan ^a   Custers, Jerome ^a   Vellinga, Jort ^a   Schuitemaker, Hanneke ^a   Goudsmit, Jaap ^a   Rodríguez, Ariane ^a  

^a CRUCELL HOLLAND BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CROSS REACTING ANTIBODY; FILOVIRUS VACCINE; IMMUNOGLOBULIN G ANTIBODY; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS VACCINE;

ADENOVIRUS; ADENOVIRUS 26; ADENOVIRUS 35; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; EBOLA VIRUS; FEMALE; FILOVIRUS; FILOVIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; MARBURG VIRUS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; T LYMPHOCYTE; TRANSGENE; VIRUS STRAIN;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; CROSS REACTIONS; EBOLA VACCINES; FEMALE; FILOVIRIDAE; GENETIC VECTORS; HEMORRHAGIC FEVER, EBOLA; IMMUNITY, HUMORAL; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES; VIRAL VACCINES;

MARBURGVIRUS; MUS; PRIMATES;

EID: 84870802724     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044115     Document Type: Article

References (66)

1. Bannister B, (2010) Viral haemorrhagic fevers imported into non-endemic countries: risk assessment and management. British medical bulletin 95: 193-225.
2. Groseth A, Feldmann H, Strong JE, (2007) The ecology of Ebola virus. Trends in Microbiology 15: 408-416.
3. Hayman DTS, Emmerich P, Yu M, Wang L-F, Suu-Ire R, et al. (2010) Long-term survival of an urban fruit bat seropositive for Ebola and Lagos bat viruses. PLoS ONE 5.
4. Leroy EM, Rouquet P, Formenty P, Souquière S, Kilbourne A, et al. (2004) Multiple Ebola virus transmission events and rapid decline of central African wildlife. Science (New York, NY) 303: 387-390.
5. Leroy EM, Epelboin A, Mondonge V, Pourrut X, Gonzalez J-P, et al. (2009) Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007. Vector borne and zoonotic diseases (Larchmont, NY) 9: 723-728.
6. Gonzalez JP, Josse R, Johnson ED, Merlin M, Georges AJ, et al. (1989) Antibody prevalence against haemorrhagic fever viruses in randomized representative Central African populations. Research in virology 140: 319-331.
7. Gonzalez JP, Nakoune E, Slenczka W, Vidal P, Morvan JM, (2000) Ebola and Marburg virus antibody prevalence in selected populations of the Central African Republic. Microbes and infection/Institut Pasteur 2: 39-44.
8. Busico KM, Marshall KL, Ksiazek TG, Roels TH, Fleerackers Y, et al. (1999) Prevalence of IgG antibodies to Ebola virus in individuals during an Ebola outbreak, Democratic Republic of the Congo, 1995. The Journal of Infectious Diseases 179 (Suppl 1):: S102-107.
9. Becquart P, Wauquier N, Mahlakõiv T, Nkoghe D, Padilla C, et al. (2010) High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon. PLoS ONE 5: e9126.
10. Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, et al. (2005) Fruit bats as reservoirs of Ebola virus. Nature 438: 575-576.
11. Towner JS, Amman BR, Sealy TK, Carroll SAR, Comer JA, et al. (2009) Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS pathogens 5: e1000536.
12. Pourrut X, Souris M, Towner JS, Rollin PE, Nichol ST, et al. (2009) Large serological survey showing cocirculation of Ebola and Marburg viruses in Gabonese bat populations, and a high seroprevalence of both viruses in Rousettus aegyptiacus. BMC infectious diseases 9: 159.
13. Towner JS, Sealy TK, Ksiazek TG, Nichol ST, (2007) High-throughput molecular detection of hemorrhagic fever virus threats with applications for outbreak settings. The Journal of Infectious Diseases 196 (Suppl 2):: S205-212.
14. Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, et al. (2006) Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Medicine 3: e177.
15. Hensley LE, Mulangu S, Asiedu C, Johnson J, Honko AN, et al. (2010) Demonstration of Cross-Protective Vaccine Immunity against an Emerging Pathogenic Ebolavirus Species. PLoS pathogens 6: e1000904.
16. Geisbert TW, Bailey M, Geisbert JB, Asiedu C, Roederer M, et al. (2010) Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates. Journal of Virology 84: 10386-10394.
17. Pratt WD, Wang D, Nichols DK, Luo M, Woraratanadharm J, et al. (2010) Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clinical and vaccine immunology: CVI 17: 572-581.
18. Geisbert TW, Bausch DG, Feldmann H, (2010) Prospects for immunisation against Marburg and Ebola viruses. Reviews in Medical Virology 20: 344-357.
19. Reed DS, Mohamadzadeh M, (2007) Status and challenges of filovirus vaccines. Vaccine 25: 1923-1934.
20. Bradfute SB, Dye JM, Bavari S, (2011) Filovirius vaccines. Human vaccines 7: 701-711.
21. Daddario-DiCaprio KM, Geisbert TW, Geisbert JB, Ströher U, Hensley LE, et al. (2006) Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. Journal of Virology 80: 9659-9666.
22. Jones SM, Feldmann H, Ströher U, Geisbert JB, Fernando L, et al. (2005) Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nature Medicine 11: 786-790.
23. Geisbert TW, Geisbert JB, Leung A, Daddario-DiCaprio KM, Hensley LE, et al. (2009) Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. Journal of Virology 83: 7296-7304.
24. Abbink P, Lemckert AAC, Ewald BA, Lynch DM, Denholtz M, et al. (2007) Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. Journal of Virology 81: 4654-4663.
25. Ersching J, Hernandez MIM, Cezarotto FS, Ferreira JDS, Martins AB, et al. (2010) Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys. Virology 407: 1-6.
26. Mast TC, Kierstead L, Gupta SB, Nikas AA, Kallas EG, et al. (2010) International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 28: 950-957.
27. Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, et al. (2011) International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 29: 5203-5209.
28. Barouch DH, Pau MG, Custers JHHV, Koudstaal W, Kostense S, et al. (2004) Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. Journal of immunology (Baltimore, Md: 1950) 172: 6290-6297.
29. Radosevic K, Rodriguez A, Lemckert AAC, van der Meer M, Gillissen G, et al. (2010) The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert. Clinical and vaccine immunology: CVI 17: 1687-1694.
30. Radosević K, Rodriguez A, Lemckert A, Goudsmit J, (2009) Heterologous prime-boost vaccinations for poverty-related diseases: advantages and future prospects. Expert review of vaccines 8: 577-592.
31. Liu J, O'Brien KL, Lynch DM, Simmons NL, La Porte A, et al. (2009) Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457: 87-91.
32. Liu J, Ewald BA, Lynch DM, Denholtz M, Abbink P, et al. (2008) Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. Journal of Virology 82: 4844-4852.
33. Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert J, et al. (2011) Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. Journal of Virology 85: 4222-4233.
34. Sullivan NJ, Martin JE, Graham BS, Nabel GJ, (2009) Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nature Reviews Microbiology 7: 393-400.
35. Sullivan NJ, Hensley L, Asiedu C, Geisbert TW, Stanley D, et al. (2011) CD8(+) cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nature Medicine.
36. Oswald WB, Geisbert TW, Davis KJ, Geisbert JB, Sullivan NJ, et al. (2007) Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS pathogens 3: e9.
37. Jahrling PB, Geisbert JB, Swearengen JR, Larsen T, Geisbert TW, (2007) Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. The Journal of Infectious Diseases 196 (Suppl 2):: S400-403.
38. Jahrling PB, Geisbert J, Swearengen JR, Jaax GP, Lewis T, et al. (1996) Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Archives of virology Supplementum 11: 135-140.
39. Jahrling PB, Geisbert TW, Geisbert JB, Swearengen JR, Bray M, et al. (1999) Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. The Journal of Infectious Diseases 179 (Suppl 1):: S224-234.
40. Dye JM, Herbert AS, Kuehne AI, Barth JF, Muhammad MA, et al. (2012) Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci U S A 109: 5034-5039.
41. Edgar RC, (2004) MUSCLE: a multiple sequence alignment method with reduced time and space complexity. BMC bioinformatics 5: 113.
42. Havenga M, Vogels R, Zuijdgeest D, Radosevic K, Mueller S, et al. (2006) Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells. The Journal of general virology 87: 2135-2143.
43. Maizel JV, White DO, Scharff MD, (1968) The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 36: 115-125.
44. Fallaux FJ, Kranenburg O, Cramer SJ, Houweling A, Van Ormondt H, et al. (1996) Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Human Gene Therapy 7: 215-222.
45. Ophorst OJAE, Radosević K, Klap JM, Sijtsma J, Gillissen G, et al. (2007) Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant. Vaccine 25: 6501-6510.
46. Kuhn JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, et al. (2010) Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Archives of Virology.
47. Swenson DL, Warfield KL, Larsen T, Alves DA, Coberley SS, et al. (2008) Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert review of vaccines 7: 417-429.
48. Olinger GG, Bailey MA, Dye JM, Bakken R, Kuehne A, et al. (2005) Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins. Journal of Virology 79: 14189-14196.
49. Rodríguez A, Mintardjo R, Tax D, Gillissen G, Custers J, et al. (2009) Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys. Vaccine 27: 6226-6233.
50. Towner JS, Khristova ML, Sealy TK, Vincent MJ, Erickson BR, et al. (2006) Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. Journal of Virology 80: 6497-6516.
51. Rodriguez LL, De Roo A, Guimard Y, Trappier SG, Sanchez A, et al. (1999) Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. The Journal of Infectious Diseases 179 (Suppl 1):: S170-176.
52. Leroy EM, Baize S, Mavoungou E, Apetrei C, (2002) Sequence analysis of the GP, NP, VP40 and VP24 genes of Ebola virus isolated from deceased, surviving and asymptomatically infected individuals during the 1996 outbreak in Gabon: comparative studies and phylogenetic characterization. The Journal of general virology 83: 67-73.
53. Lauring AS, Andino R, (2010) Quasispecies theory and the behavior of RNA viruses. PLoS pathogens 6: e1001005.
54. Sanjuán R, Nebot MR, Chirico N, Mansky LM, Belshaw R, (2010) Viral mutation rates. Journal of Virology 84: 9733-9748.
55. Holmes EC, (2009) The evolution and emergence of RNA viruses. pp. 254.
56. Sanchez A, Lukwiya M, Bausch D, Mahanty S, Sanchez AJ, et al. (2004) Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. Journal of Virology 78: 10370-10377.
57. Rhee EG, Kelley RP, Agarwal I, Lynch DM, La Porte A, et al. (2010) TLR4 ligands augment antigen-specific CD8+ T lymphocyte responses elicited by a viral vaccine vector. Journal of Virology 84: 10413-10419.
58. Shott JP, McGrath SM, Pau MG, Custers JHV, Ophorst O, et al. (2008) Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice. Vaccine 26: 2818-2823.
59. Obar J, Khanna K, Lefrancois L, (2008) Endogenous Naive CD8+ T Cell Precursor Frequency Regulates Primary and Memory Responses to Infection. Immunity 28: 859-869.
60. Kotturi MF, Scott I, Wolfe T, Peters B, Sidney J, et al. (2008) Naive precursor frequencies and MHC binding rather than the degree of epitope diversity shape CD8+ T cell immunodominance. Journal of immunology (Baltimore, Md: 1950) 181: 2124-2133.
61. Alazard-Dany N, Volchkova V, Reynard O, Carbonnelle C, Dolnik O, et al. (2006) Ebola virus glycoprotein GP is not cytotoxic when expressed constitutively at a moderate level. The Journal of general virology 87: 1247-1257.
62. Francica JR, Varela-Rohena A, Medvec A, Plesa G, Riley JL, et al. (2010) Steric shielding of surface epitopes and impaired immune recognition induced by the ebola virus glycoprotein. PLoS pathogens 6.
63. Swenson DL, Wang D, Luo M, Warfield KL, Woraratanadharm J, et al. (2008) Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clinical and vaccine immunology: CVI 15: 460-467.
64. Qiu X, Fernando L, Alimonti JB, Melito PL, Feldmann F, et al. (2009) Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS ONE 4: e5547.
65. Honeyman MC, Brusic V, Stone NL, Harrison LC, (1998) Neural network-based prediction of candidate T-cell epitopes. Nature Biotechnology 16: 966-969.
66. Rammensee HG, Friede T, Stevanoviíc S, (1995) MHC ligands and peptide motifs: first listing. Immunogenetics 41: 178-228.